Expression of an activated mammalian target of rapamycin in adenocarcinoma of the cervix: A potential biomarker and molecular target therapy

Molecular Carcinogenesis

Volumn 47, Issue 6, 2008, Pages 446-457

  Faried, Leri S ^a,b   Faried, Ahmad ^a   Kanuma, Tatsuya ^a   Aoki, Hiroshi ^a   Sano, Takaaki ^a   Nakazato, Tomoko ^a   Tamura, Tomohiro ^a   Kuwano, Hiroyuki ^a   Minegishi, Takashi ^a  

^a GUNMA UNIVERSITY   (Japan)

^b GUNMA UNIVERSITY   (Japan)

Author keywords

Adenocarcinoma of the cervix; Cisplatin; p Akt; p mTOR

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CISPLATIN; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE;

ADULT; AGED; APOPTOSIS; ARTICLE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UTERINE CERVIX CARCINOMA; WESTERN BLOTTING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; PROGNOSIS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

MAMMALIA;

EID: 44949112425     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20402     Document Type: Article

References (33)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB. Cancer incidence in five continents, Vol. VIII. Lyon: IARC Press; 2002.
3. Bray F, Carstensen B, Moller H, et al. Incidence trends of adenocarcinoma of the cervix in 13 European countries. Cancer Epidemiol Biomarkers Prev 2005;14:2191-2199.
4. Zheng T, Holford T, Ma Z, et al. The continuing increase in adenocarcinoma of the uterine cervix: A birth cohort phenomenon. Int J Epidemiol 1996;25:252-258.
5. Vizcaino AP, Moreno V, Bosch FX, Munoz N, Barros-Dios XM, Parkin DM. International trends in the incidence of cervical cancer: I. Adenocarcinoma and adenosquamous cell carcinomas. Int J Cancer 1998;75:536-545.
6. Smith HO, Tiffany MF, Qualls CR, Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States - A 24 year population based study. Gynecol Oncol 2000;78:97-105.
7. Farley JH, Hickey KW, Carlson JW, Rose GS, Kost ER, Harrison TA. Adenosquamous histology predicts a poor outcome for patients with advanced-stage, but not early stage, cervical carcinoma. Cancer 2003;97:2196-2202.
8. Lea JS, Sheets EE, Wenham RM, et al. Stage IIB-IVB cervical adenocarcinoma: Prognostic factors and survival. Gynecol Oncol 2002;84:115-119.
9. Yasuda S, Kojima A, Maeno Y, et al. Poor prognosis of patients with stage Ib1 adenosquamous cell carcinoma of the uterine cervix with pelvic lympnode metastasis. Kobe J Med Sci 2006;51:9-15.
10. Perez CA, Kurman RJ, Stehman FB, Thigpen JT. Uterine cervix. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott; 1992. pp 591-662.
11. Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: A gynecologic oncology group study. J Clin Oncol 2001;19:1275-1278,
12. Altomare DA, Wang HQ, Skele KL, et al. Akt and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004;23:5853-5857.
13. Kremer CL, Klein RR, Mendelson J, et al. Expression of mTOR signaling pathway markers in prostate cancer progression. Prostate 2006;66:1203-1212.
14. Yang X, Fraser M, Moll UM, Basak A, Tsang BK. Akt-mediated cisplatin resistance in ovarian cancer: Modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 2006;66:3126-3136.
15. Faried LS, Faried A, Kanuma T, et al. Inhibition of the mammalian target of rapamycin (mTOR) by rapamycin increases chemosensitivity of CaSki cells to paclitaxel. Eur J Cancer 2006;42:934-947.
16. Faried LS, Faried A, Kanuma T, et al. Predictive and prognostic role of activated mammalian target of rapamycin in cervical cancer treated with cisplatin-based neoadjuvant chemotherapy. Oncol Rep 2006;16:57-63.
17. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-Akt pathway in uterine cervical neoplasia: Frequent PIK3CA amplification and Akt phosphorylation. Int J Cancer 2006;118:1877-1883.
18. Creasman WT. New gynecologic cancer staging. Gynecol Oncol 1995;58:157-158.
19. Chou TC, Talalay P. Quantitative analysis of dose-effect relationship: The combined effects of multiple drugs on enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
20. Altomare DA, Testa JR. Perturbations of the Akt signaling pathway in human cancer. Oncogene 2005;24:7455-7464.
21. Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005;4:650-658.
22. Soufla G, Sifakis S, Baritaki S, Zafiropoulos A, Koumantakis E, Spandidos DA. VEGF, FGF2, TGFB1 and TGFBR1 mRNA expression levels correlate with the malignant transformation of the uterine cervix. Cancer Lett 2005;221:105-118.
23. Ma YY, Wei SJ, Lin YC, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000;19:2739-2744.
24. Kang S, Bader AG, Vogt PK. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci USA 2005;102:802-807.
25. Granville CA, Memmott RM, Gills JJ, Dennis PA. Handicapping the race to develop inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway. Clin Cancer Res 2006;12:679-689.
26. Belyanskaya LL, Hopkins-Donaldson S, Kurtz S, et al. Cisplatin activates Akt in small cell lung cancer cells and attenuates apoptosis by survivin upregulation. Int J Cancer 2005;117:755-763.
27. O'Reilly KE, Rojo F, She QB, et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006;66:1500-1508.
28. Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD. Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors. Mol Cancer Ther 2006;5:2676-2684.
29. Shi Y, Frankel A, Radvanyi LG, Penn LZ, Miller RG, Mills GB. Rapamycin enhances apoptosis and increases sensitivity to cisplatin in vitro. Cancer Res 1995;55:1982-1982.
30. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120747-759.
31. Wu C, Wangpaichitr M, Feun L, et al. Overcoming cisplatin resistance by mTOR inhibitor in lung cancer. Mol Cancer 2005;4:25.
32. Mabuchi S, Altomare DA, Cheung M, et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007;13:4261-4270.
33. Li S, Takasu T, Perlman DM, et al. Translation factor elF4E rescues cells from Myc-dependent apoptosis by inhibiting cytochrome c release. J Biol Chem 2003;278:3015-3022.